A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency

An Open-Label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of SR604 Injection in Patients With Congenital Coagulation Factor VII Deficiency

This is an open-label, multicenter, exploratory Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of SR604 Injection in patients with congenital coagulation Factor VII deficiency.

Study Overview

• Status: Not yet recruiting
• Conditions: Factor VII Deficiency
• Intervention / Treatment: Drug: SR604

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Research and Development; Phone Number: 862122130888; Email: hanyu@raas-corp.com

Study Locations

• China
  • Tianjin, China
    • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥12 years and ≤65 years at the time of signing the informed consent form; both genders eligible;
2. Clinically diagnosed with congenital coagulation Factor VII deficiency, with historical or screening FVII activity <10%, and ≥2 treated new-onset bleeding events within 3 months prior to enrollment;
3. No active bleeding symptoms prior to first administration of SR604 Injection;
4. The subject and/or legal representative and impartial witness have signed the informed consent form, indicating voluntary agreement to participate in this trial, to provide biological samples for testing as required by the protocol, and to comply with the planned study visits;
5. Female subjects (post-menarche) must have a negative serum pregnancy test (HCG) during the screening period; subjects with childbearing potential (females post-menarche or males post-spermarche) must agree to use highly effective contraceptive measures throughout the study period.

Exclusion Criteria:

1. Known history of hypersensitivity to the study drug formulation or any of its components;
2. Intolerance to subcutaneous injection or other local skin abnormalities or dermatoses that may affect drug administration or safety assessment;

3. Meeting any one of the following criteria during screening:

   1. Hemoglobin <60 g/L;
   2. Platelet count <100×10⁹/L;
   3. Abnormal hepatic or renal function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.5× upper limit of normal (ULN), or total bilirubin ≥1.5× ULN; or serum creatinine (Cr) ≥1.5× ULN;
   4. Positive for anti-human immunodeficiency virus (HIV) antibodies.
4. Any bleeding disorder other than congenital Factor VII deficiency, or other conditions causing significantly abnormal coagulation parameters (e.g., hemophilia A or B, von Willebrand disease, platelet disorders, vitamin K deficiency, etc.);
5. Protein C deficiency or Protein S deficiency;
6. History of thrombosis, family history of thrombosis, or history of thrombophilia;
7. Intracranial hemorrhage within 2 years prior to signing the informed consent form;
8. Severe cardiac disease, such as unstable angina, congestive heart failure (New York Heart Association class ≥III), serious arrhythmia (QTc interval >450 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), etc.;
9. Female patients with menstrual abnormalities caused by organic gynecological conditions (e.g., uterine fibroids, endometriosis, adenomyosis, etc.);
10. Received Factor VII-containing products within 48 hours prior to first administration of SR604 Injection; received whole blood or plasma transfusion within 2 weeks prior to first administration of SR604 Injection;
11. Used any anticoagulants, antifibrinolytics, or agents affecting platelet function (including chemical drugs, biological products, or traditional Chinese medicine), including aspirin, within 1 week prior to screening, or required use of such agents during the treatment period;
12. Underwent major surgery (defined as Grade III or IV surgery) within 1 month prior to signing the informed consent form, or planned to undergo surgery during the study period;
13. Enrolled in other clinical trials within 1 month prior to signing the informed consent form;
14. Miscarriage or pregnancy termination within 3 months prior to signing the informed consent form; pregnant or breastfeeding women;
15. Mental illness or significant psychiatric disorder, or incapacity or lack of cognitive ability due to other causes;

16. Other conditions deemed by the investigator to be unsuitable for enrollment, such as alcoholism, anticipated poor subject compliance preventing completion of dosing and study follow-up, poorly controlled comorbid chronic diseases, or serious systemic diseases.

    -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SR604：Multiple-dose exploratory efficacy trial consists of 2 cohorts; Participants with FVII deficiency will receive SR604 dose 1/2 as multiple SC injections every 4-weeks	Drug: SR604; SR604 will be administered as SC injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Treated overall Annualized Bleeding Rate (ABR)	Through 28 weeks of treatment.

Secondary Outcome Measures

Outcome Measure	Time Frame
Treated spontaneous annualized bleeding rate	over 28 weeks of treatment
Treated overall annualized joint bleeding rate	over 28 weeks of treatment
Overall annualized bleeding rate including treated and untreated bleeding events	over 28 weeks of treatment,
Annualized menorrhagia bleeding rate (menstruating females only)	over 28 weeks of treatment
Change in PBAC score (menstruating females only);	From baseline over 28 weeks of treatment
Change in EQ-5D-5L health index score	From pre-treatment over 28 weeks of treatment
Change in EQ-VAS score	From baseline over 28 weeks of treatment;
Subject overall satisfaction score with treatment efficacy	over 28 weeks of treatment

Other Outcome Measures

Outcome Measure	Time Frame
Single-dose pharmacokinetic (PK) parameters:Time to Peak Plasma Concentration (Tmax)	over 28 weeks of treatment
Single-dose pharmacokinetic (PK) parameters:Peak Plasma Concentration (Cmax)	over 28 weeks of treatment
Single-dose pharmacokinetic (PK) parameters:Area Under the Concentration-Time Curve from Zero to Last Quantifiable Time Point (AUC0-t)	over 28 weeks of treatment
Multiple-dose pharmacokinetic parameters-Time to Peak Plasma Concentration (Tmax)	over 28 weeks of treatment
Multiple-dose pharmacokinetic parameters-Peak Plasma Concentration (Cmax)	Over 28 weeks of treatment
Safety and Immunogenicity:Incidence of AEs/SAEs/AESI,	over 28 weeks of treatment
Incidence of drug-related AEs/SAEs/AESIs	over 28 weeks of treatment
Safety and Immunogenicity: Anti-drug antibody (ADA) and neutralizing antibody (NAb) - number of subjects and incidence rate.	over 28 weeks of treatment

Collaborators and Investigators

• Sponsor: Shanghai RAAS Blood Products Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: July 14, 2026
• First Submitted That Met QC Criteria: July 14, 2026
• First Posted (Actual): July 17, 2026

Study Record Updates

• Last Update Posted (Actual): July 17, 2026
• Last Update Submitted That Met QC Criteria: July 14, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Hematologic Diseases; Blood Coagulation Disorders; Hemorrhagic Disorders; Blood Coagulation Disorders, Inherited; Coagulation Protein Disorders; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases; Factor VII Deficiency
• Other Study ID Numbers: LS-SR604-VII-II01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No